received Food and Drug Administration clearance to sell its attention-deficit hyperactivity treatment, Strattera.
The company hopes to have the drug on the market by January.
The approval was pressuring shares of
, which sells the hyperactivity treatment Adderall. Lilly's treatment is believed to be less likely to be abused because it isn't a stimulant.
Lilly's shares ended down about 6% at $64 Tuesday after the company said it's cautious about its earnings prospects for 2003. They were about 3% higher at $66 on the Instinet premarket session Wednesday. Shire's shares were off 12% at $20.94.